PMBL is classified as midway in the biologic spectrum between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma [3] with overexpression of genes in signaling pathways of NF-kB and Janus kinase (JAK)/signal transducer and transcription (STAT), high expression of CD20, downregulation of major histocompatibility class I and II molecules and overexpression of programmed death ligands [2, 5–9]. Here, NFKB1 is linked to diffuse large B-cell lymphoma.